Article summary
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published an article which emphasises that the narrow definition of unmet medical needs in the General Pharmaceutical Legislation may hinder the development of new treatments, particularly for chronic conditions. This has led to EU Member States calling for clear criteria to be established in the legislation for unmet medical needs, however, the EFPIA states this is a nearly impossible task. Instead, the EFPIA calls for a science-based definition that includes patient insights, ensuring equitable consideration across all disease areas to foster innovation.
To continue reading this news article, as well as thousands of others like it, sign in with LexisNexis or register for a free trial